Meta-analysis of clinical efficacy and safety of Compound Danshen Dripping Pills combined with conventional antihypertensive drugs in treatment of hypertensive left ventricular hypertrophy.
10.19540/j.cnki.cjcmm.20210222.502
- Author:
Zhe CHEN
1
;
Ying-Ying PENG
2
;
Feng-Wen YANG
1
;
Hai-Yin HU
1
;
Chun-Xiang LIU
1
;
Jun-Hua ZHANG
1
Author Information
1. Tianjin University of Traditional Chinese Medicine Tianjin 301617, China Evidence-based Medicine Center, Tianjin University of Traditional Chinese Medicine Tianjin 301617, China.
2. Tianjin University of Traditional Chinese Medicine Tianjin 301617, China First Teaching Hospital of Tianjin University of Traditional Chinese Medicine Tianjin 300381, China.
- Publication Type:Meta-Analysis
- Keywords:
Compound Danshen Dripping Pills;
Meta-analysis;
efficacy;
hypertensive left ventricular hypertrophy;
safety;
systematic evaluation
- MeSH:
Antihypertensive Agents/adverse effects*;
China;
Drugs, Chinese Herbal/adverse effects*;
Humans;
Hypertrophy, Left Ventricular/drug therapy*;
Stroke Volume;
Treatment Outcome;
Ventricular Function, Left
- From:
China Journal of Chinese Materia Medica
2021;46(10):2578-2587
- CountryChina
- Language:Chinese
-
Abstract:
To systematically evaluate the clinical efficacy and safety of Compound Danshen Dripping Pills combined with conventional antihypertensive drugs in the treatment of hypertensive left ventricular hypertrophy. China National Knowledge Infrastructure(CNKI), Wanfang, VIP, PubMed, EMbase, Cochrane Library, Ovid and Web of Science databases were searched by computer to retrieve the randomized controlled trials(RCTs) of Compound Danshen Dripping Pills combined with conventional antihypertensive drugs in the treatment of hypertensive left ventricular hypertrophy from the establishment of databases to July 2020. After two researchers performed data retrieval, data extraction, and risk assessment of bias, they used RevMan 5.3 software for Meta-analysis. A total of 10 RCTs were included, with a total of 979 patients. Meta-analysis results showed that in terms of interventricular septal thickness(MD=-0.70, 95%CI[-1.15,-0.24], P=0.003), left ventricular posterior wall thickness(MD=-0.81, 95%CI[-1.41,-0.21], P=0.008), left ventricular mass index(MD=-8.75, 95%CI[-17.40,-0.10], P=0.05), systolic blood pressure(MD=-8.97, 95%CI[-13.46,-4.48], P<0.000 1), diastolic blood pressure(MD=-5.87, 95%CI[-8.39,-3.34], P<0.000 01) and left ventricular end-diastolic diameter(MD=-1.73, 95%CI[-2.38,-1.08], P<0.000 01), Compound Danshen Dripping Pills combined with conventional antihypertensive drugs was superior to conventional antihypertensive drugs. In terms of left ventricular ejection fraction(MD=0.41, 95%CI[-0.74, 1.55], P=0.49), there was no statistical difference in treatment between the two groups. Because of the small amount of literatures included in the safety aspect, it is impossible to give an accurate conclusion. The GRADE score showed that the level of evidence was low and extremely low. The results show that the Compound Danshen Dripping Pills combined with conventional antihypertensive drugs may effectively improve the clinical efficacy for hypertensive ventricular hypertrophy, and the safety needs to be further explored. Due to the low quality of the included literatures, more high-quality RCTs are needed for verification.
